A Randomized, Double-blind, Placebo-controlled, Multicenter Phase II Clinical Trial to Compare the Efficacy and Safety of Fruquintinib Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Patients With CRC as 3rd or Above Therapy

Trial Profile

A Randomized, Double-blind, Placebo-controlled, Multicenter Phase II Clinical Trial to Compare the Efficacy and Safety of Fruquintinib Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Patients With CRC as 3rd or Above Therapy

Completed
Phase of Trial: Phase II

Latest Information Update: 22 Feb 2016

At a glance

  • Drugs Fruquintinib (Primary)
  • Indications Colorectal cancer
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Hutchison MediPharma
  • Most Recent Events

    • 18 Feb 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 14 Sep 2015 Results published in a Hutchison China MediTech media release.
    • 04 Sep 2015 Detailed results from this trial will be presented at the 2015 European Cancer Congress meeting in late September, according to a Hutchison MediPharma media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top